ABEONA THERAPEUTICS INC.

# Signal Note: Deerfield Initiates ABEO Position Deerfield's $211K entry into Abeona suggests conviction in the company's gene therapy pipeline, likely driven by upcoming clinical catalysts in its lead programs: ABO-102 for CLN1 disease (a rare lysosomal storage disorder) and ABO-101 for MPSD. The position size is modest but notable given Deerfield's selective healthcare investing approach, indicating they may see value ahead of near-term data readouts or regulatory milestones that could derisk the asset.